UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer

Anticancer research, 2018-12, Vol.38 (12), p.6771-6782

2018

Link zum Volltext

Verfügbarkeit prüfen

Real‐life effectiveness of first‐line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry

Thoracic cancer, 2020-11, Vol.11 (11), p.3346-3356

2020

Link zum Volltext

Verfügbarkeit prüfen

Care of patients with non-small-cell lung cancer stage III – the Central European real-world experience

Radiology and oncology, 2020-05, Vol.54 (2), p.209-220

2020

Link zum Volltext

Verfügbarkeit prüfen

Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial

Cancer treatment and research communications, 2021, Vol.28, p.100427-100427, Article 100427

2021

Link zum Volltext

Verfügbarkeit prüfen

Lung cancer, pulmonary emphysema and pleural effusion: An autopsy study

Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2015-12, Vol.159 (4), p.642-647

2015

Link zum Volltext

Verfügbarkeit prüfen

Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world set-up

PloS one, 2017-07, Vol.12 (7), p.e0181803

2017

Link zum Volltext

Verfügbarkeit prüfen

Pemetrexed in the Second Line Chemotherapy of Non-small Cell Lung Cancer. A Multicentre Prospective Analysis of Data From Clinical Practice

Chest, 2011-10, Vol.140 (4), p.308A-308B

2011

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer

Journal of cancer research and clinical oncology, 2023-12, Vol.149 (19), p.17123-17131

2023

Link zum Volltext

Verfügbarkeit prüfen

Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer

In vivo (Athens), 2023-09, Vol.37 (5), p.2229-2236

2023

Link zum Volltext

Verfügbarkeit prüfen

Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?

Anticancer research, 2022-04, Vol.42 (4), p.1987-1995

2022

Link zum Volltext

Verfügbarkeit prüfen

Non-small Cell Lung Cancer as a Chronic Disease - A Prospective Study from the Czech TULUNG Registry

In vivo (Athens), 2020-01, Vol.34 (1), p.369-379

2020

Link zum Volltext

Verfügbarkeit prüfen

Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study

Anticancer research, 2021-04, Vol.41 (4), p.2059-2065

2021

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment

Anticancer research, 2021-05, Vol.41 (5), p.2597-2603

2021

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer

Anticancer research, 2021-11, Vol.41 (11), p.5625-5634

2021

Link zum Volltext

Verfügbarkeit prüfen

Case report of a patient with metastatic non-small cell lung cancer with positive ALK gene rearrangement treated in the first line with alectinib

Onkologie (Olomouc), 2020-06, Vol.14 (Suppl.D), p.71-74

Koubková, Leona

2020

Link zum Volltext

Verfügbarkeit prüfen

Real‐life effectiveness of first‐line anticancer treatments in stage IIIB / IV NSCLC patients: Data from the C zech TULUNG R egistry

Thoracic cancer, 2020-11, Vol.11 (11), p.3346-3356

2020

Link zum Volltext

Verfügbarkeit prüfen

Antiangiogenic therapy of lung cancer

Onkologie (Olomouc), 2018-10, Vol.12 (5), p.231-234

Koubková, Leona

2018

Link zum Volltext

Verfügbarkeit prüfen

P3.02b-082 Gefitinib in First-Line Treatment of Caucasian Patients with NSCLC and EGFR Mutations in Exons 19 or 21

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1240-S1241

2017

Link zum Volltext

Verfügbarkeit prüfen

P2.03a-026 Pemetrexed (Alimta) in Maintenance Therapy of 194 Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC): Topic: Clinical Trials

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S903-S904

2017

Link zum Volltext

Verfügbarkeit prüfen

P3.02b-082 Gefitinib in First-Line Treatment of Caucasian Patients with NSCLC and EGFR Mutations in Exons 19 or 21: Topic: EGFR Clinical

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1240-S1241

2017

Link zum Volltext

Verfügbarkeit prüfen

P2.03a-026 Pemetrexed (Alimta) in Maintenance Therapy of 194 Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S903-S904

2017

Link zum Volltext

Verfügbarkeit prüfen

P2.02-011 Management of Non-Small-Cell Lung Cancer (NSCLC) Stage III Patients in Central European Countries: Topic: Clinical Outcome

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S852-S853

2017

Link zum Volltext

Verfügbarkeit prüfen

P2.02-011 Management of Non-Small-Cell Lung Cancer (NSCLC) Stage III Patients in Central European Countries

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S852-S853

2017

Link zum Volltext

Verfügbarkeit prüfen

Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic

Klinická onkologie, 2018, Vol.31 (3), p.207-212

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(36)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(14)
Life Sciences & Biomedicine
(13)
Humans
(12)
Lung Cancer
(11)
Oncology
(11)
Female
(10)
Male
(10)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(9)
Lung Neoplasms - Drug Therapy
(9)
Middle Aged
(9)
Aged
(8)
Non-Small Cell Lung Carcinoma
(8)
Adult
(6)
Carcinoma, Non-Small-Cell Lung - Pathology
(6)
Lung Neoplasms - Mortality
(6)
Non-Small Cell Lung Cancer
(6)
Small Cell Lung Carcinoma
(6)
Carcinoma, Non-Small-Cell Lung - Mortality
(5)
Chemotherapy
(5)
Lung Neoplasms - Pathology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer

Real‐life effectiveness of first‐line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry

Care of patients with non-small-cell lung cancer stage III – the Central European real-world experience

Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial

Lung cancer, pulmonary emphysema and pleural effusion: An autopsy study

Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world set-up

Pemetrexed in the Second Line Chemotherapy of Non-small Cell Lung Cancer. A Multicentre Prospective Analysis of Data From Clinical Practice

Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer

Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?

Non-small Cell Lung Cancer as a Chronic Disease - A Prospective Study from the Czech TULUNG Registry

Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study

Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment

Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer

Case report of a patient with metastatic non-small cell lung cancer with positive ALK gene rearrangement treated in the first line with alectinib

Real‐life effectiveness of first‐line anticancer treatments in stage IIIB / IV NSCLC patients: Data from the C zech TULUNG R egistry

Antiangiogenic therapy of lung cancer

P3.02b-082 Gefitinib in First-Line Treatment of Caucasian Patients with NSCLC and EGFR Mutations in Exons 19 or 21

P2.03a-026 Pemetrexed (Alimta) in Maintenance Therapy of 194 Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC): Topic: Clinical Trials

P3.02b-082 Gefitinib in First-Line Treatment of Caucasian Patients with NSCLC and EGFR Mutations in Exons 19 or 21: Topic: EGFR Clinical

P2.03a-026 Pemetrexed (Alimta) in Maintenance Therapy of 194 Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)

P2.02-011 Management of Non-Small-Cell Lung Cancer (NSCLC) Stage III Patients in Central European Countries: Topic: Clinical Outcome

P2.02-011 Management of Non-Small-Cell Lung Cancer (NSCLC) Stage III Patients in Central European Countries

Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic

Suchergebnisse filtern